Somatostatin through its specific receptor inhibits spontaneous and TNF-α- and bacteria-induced IL-8 and IL-1β secretion from intestinal epithelial cells

Journal of Immunology

Volumn 165, Issue 6, 2000, Pages 2955-2961

  Chowers, Y ^a   Cahalon, L ^a   Lahav, M ^a   Schor, H ^a   Tal, R ^a   Bar Meir, S ^a   Levite, M ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 8; OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONCENTRATION RESPONSE; CORRELATION FUNCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; MUCOSA INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SALMONELLA; TRANSCRIPTION REGULATION;

EID: 0034665089     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.6.2955     Document Type: Article

References (50)

1. Differential cytokine expression by human intestinal epithelial cell lines: Regulated expression of interleukin 8
2. Rapid expression of IL-1β by intestinal epithelial cells in vitro
3. NO-dependent and NO-independent IL-1 production by a human colonic epithelial cell line under inflammatory stress
4. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells
5. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion
6. Chemokines in the inflammatory bowel diseases
7. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: Evidence for a biological role for IL-8 in inflammation of the colon
8. Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD)
9. Imbalance of the interleukin 1 system in colonic mucosa: Association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2
10. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
11. Gastrointestinal somatostatin: Distribution, secretion and physiological significance
12. Immunocytochemical localization of prosomatostatin fragments in maturing and mature secretory granules of pancreatic and gastrointestinal D cells
13. Appearance of gastrin and somatostatin in the human fetal stomach, duodenum and pancreas
14. Types of endocrine cells in the human colon and rectum
15. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae
16. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat
17. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues
18. Octreotide
19. Suppressed colony formation of peripheral blood lymphocytes in a patient with somatostatinoma
20. Somatostatin and the immune and haematopoietic system: A review
21. Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin
22. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype
23. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
24. Classification and nomenclature of somatostatin receptors
25. Somatostatin antagonist analog increases GH, insulin, and glucagon release in the rat
26. Evidence that endogenous somatostatin (SRIF) exerts an inhibitory control on the function and growth of rat adrenal zona glomerulosa: The possible involvement of zona medullaris as a source of endogenous SRIF
27. Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease
28. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease
29. Tumour necrosis factor-α and interferon-γ production measured at the single cell level in normal and inflamed human intestine
30. Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies
31. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
32. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
33. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
34. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
35. Somatostatin in human follicular fluid
36. Somatostatin in physiological concentrations inhibits basal and enhances luteinizing hormone-stimulated progesterone release from human granulosa-luteal cells
37. Somatostatin (SRIF) stimulates the release of interleukin-6 (IL-6) from human peripheral blood monocytes (PBM) in vitro
38. Chemokine receptor expression by human intestinal epithelial cells
39. Modulation of cytokine production in activated human monocytes by somatostatin
40. Effects of somatostatin on human intestinal lamina propria lymphocytes: Modulation of lymphocyte activation
41. Somatostatin analogues suppress the inflammatory reaction in vivo
42. Effect of somatostatin on β-endorphin release in rat experimental chronic inflammation
43. Granuloma T lymphocytes in murine schistosomiasis mansoni have somatostatin receptors and respond to somatostatin with decreased IFN-γ secretion
44. Substance P and somatostatin can modulate the amount of IgG2a secreted in response to schistosome egg antigens in murine schistosomiasis mansoni
45. Substance P regulates somatostatin expression in inflammation
46. The substance P and somatostatin interferon-γ immunoregulatory circuit
47. Octreotide effectively decreases mucosal damage in experimental colitis
48. Modulation of synovial cell function by somatostatin in patients with rheumatoid arthritis
49. Somatostatin and its receptor family
50. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer